Home » GSK and Vir Biotech Partner on Coronavirus Treatments
GSK and Vir Biotech Partner on Coronavirus Treatments
GSK and Vir Biotech have teamed up to develop a COVID-19 vaccine and they aim to begin a phase 2 trial in the next three to four months.
Vir’s current product development pipeline targets hepatitis B virus, influenza A, SARS-CoV-2, human immunodeficiency virus and tuberculosis.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May